Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00056368
Status:
COMPLETED
Last Update Posted:
2008-10-21
First Post:
2003-03-11
Brief Title:
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Double-Blind Randomized Multi-Center Study of the Safety and Efficacy of Anidulafungin vs Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections These infections due to yeast a type of fungus in the mouthesophagus in the blood or in other areas within the body
Detailed Description:
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis candidemia and other invasive fungal infections Anidulafungin is an antifungal agent of the echinocandin class which targets the fungal cell wall of yeast and other filamentous fungi
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A8851002 | None | None | None |